PTGER1
Prostaglandin E2 receptor EP1 subtype
As of the edition of 20 October 2026, PTGER1 (prostaglandin E2 receptor EP1 subtype, UniProt P34995) has 4 drugs tested at it and 8 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P34995
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Urinary and reproductive; Heart and blood vessels; Pregnancy and women's health; Nutrition and metabolism; Hormones; Cancer; Digestive system; Eye
- Registered trials of its drugs
- 78
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dinoprostone | Marketed | Phase 4 | none listed |
| Alprostadil | Marketed | Phase 4 | none listed |
| ONO-8539 | Went quiet | Phase 2 | none listed |
| Limaprost | Status not established | Phase 4 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Undetermined | 6 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Ono Pharmaceutical | Route A |
The other 6 companies at PTGER1
In the product8 companies in all; 6 are not named here, and no score is.
See the 8 companies at PTGER1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.